OPKO Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by OPKO Health, Inc. on April 1, 2016. The report discloses a specific corporate governance event regarding executive compensation approved by the Compensation Committee of the Board of Directors on the same date.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the grant of stock options and does not contain financial performance data.
Material Changes
The material change reported is the grant of stock options to named executive officers. The options vest ratably over four years and expire on the tenth anniversary of the grant date. The specific grants are as follows:
- Phillip Frost (Chairman/Chief Executive Officer): 500,000 stock options
- Jane H. Hsiao (Vice Chairman/Chief Technical Officer): 450,000 stock options
- Steven D. Rubin (Executive Vice President): 450,000 stock options
- Adam Logal (Senior Vice President/Chief Financial Officer): 250,000 stock options
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, outlook, management commentary on operations, risks, contingencies, or unusual items. The document is limited to the disclosure of the compensation committee's action.
Key Facts for Investor Verification
- Verify the total number of shares authorized for issuance under the company's equity incentive plan to ensure these grants are within limits.
- Confirm the strike price of the granted options, which is not explicitly stated in this text.
- Review the vesting schedule details to understand the retention timeline for the named executives.
- Check subsequent filings for any changes in executive leadership or compensation structure.